WO2002052954A2 - Composition nutritionnelle destinee a une pathologie osseuse - Google Patents

Composition nutritionnelle destinee a une pathologie osseuse Download PDF

Info

Publication number
WO2002052954A2
WO2002052954A2 PCT/EP2002/000296 EP0200296W WO02052954A2 WO 2002052954 A2 WO2002052954 A2 WO 2002052954A2 EP 0200296 W EP0200296 W EP 0200296W WO 02052954 A2 WO02052954 A2 WO 02052954A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
vitamin
composition
inulin
fos
Prior art date
Application number
PCT/EP2002/000296
Other languages
English (en)
Other versions
WO2002052954A3 (fr
Inventor
Denis Barclay
Ferdinand Haschke
Véronique Jaussan
Evelyn Spivey-Krobath
Claude Cavadini
Original Assignee
Societe Des Produits Nestle S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe Des Produits Nestle S.A. filed Critical Societe Des Produits Nestle S.A.
Priority to EP02702265A priority Critical patent/EP1351584A2/fr
Priority to AU2002235836A priority patent/AU2002235836A1/en
Publication of WO2002052954A2 publication Critical patent/WO2002052954A2/fr
Publication of WO2002052954A3 publication Critical patent/WO2002052954A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a nutritional composition for prevention or treatment of a bone condition, a method of production of the composition, use of the composition in the manufacture of a medicament for the prevention or treatment of a bone condition, and a method of treatment of a bone condition which comprises administering an effective amount of the composition.
  • bone condition is taken to mean a condition in which the health of osseous tissue including bone or teeth is affected. It includes an ailment selected from the group which comprises osteoporosis; osteoporotic fractures and bone fractures, typically hip and forearm fractures; as well as conditions in which deficient calcium absorption, retention, resorption or calcification is implicated.
  • composition is required to address the problems of preventing bone loss and recovery from bone trauma in the elderly as well as in clinical and performance settings.
  • composition has now been found that can be used to provide nutrition to an elderly patient as well as performance nutrition or clinical nutrition eg. to a hospital patient.
  • the invention provides a composition for prevention or treatment of a bone condition which comprises a source of protein, a source of carbohydrate, a source of fat, calcium, magnesium, zinc, vitamin D and vitamin K.
  • the invention provides a method of producing a composition according to a first aspect of the invention which comprises a step of blending the required nutrients, minerals or vitamins together in the required amounts.
  • the invention provides use of a composition according to a first aspect of the invention in the prevention or treatment of a bone condition.
  • the invention provides use of a composition according to a first aspect of the invention in the manufacture of a functional food or medicament for the prevention or treatment of a bone condition.
  • the invention provides a method of prevention or treatment of a bone condition which comprises administering an effective amount of an embodiment of a composition according to a first aspect of the invention.
  • a composition according to an embodiment of the invention comprises calcium derived from milk calcium. This is a complex form of calcium which is present in milk.
  • an embodiment of a composition according to the invention comprises one or more nutrients, minerals or vitamins selected from the group which consists of copper, vitamin E, vitamin C.
  • the embodiment comprises at least one nutrient, mineral or vitamin selected from the group that consists of soy isoflavones, inulin, fructo-oligosaccharides, caseino- glycomacropeptide (CGMP), casein phosphopeptide or a mixture thereof. Even more preferably the embodiment comprises two or more of these nutrients. Most preferably it comprises all of these nutrients.
  • inulin and fructo-oligosaccharides are provided in the form of a blend.
  • the blend has a ratio of inulin:FOS of about 20 to about 45 : about 80 to about 55 by weight. More preferably the ratio of inulin:FOS is about 30:about 70 by weight.
  • an embodiment comprises 10-110% of the recommended dietary intake for the elderly of the above nutrients, minerals or vitamins. More preferably it comprises the following amounts of nutrients, minerals or vitamins (if present) per 300 g of the composition. Preferably this is the amount of composition administered per day.
  • Calcium preferably about 120 mg to about 1200 mg, more preferably about 800 mg
  • Magnesium preferably about 42 mg to about 420 mg, more preferably about 210 mg
  • Zinc preferably about 1.5 mg to about 15 mg , more preferably about 15 mg
  • Vitamin D preferably about 1.5 ug to about 15 ug, more preferably about 10 ug
  • Vitamin K preferably about 0.8 ug to about 80 ug, more preferably about 60 ug
  • Copper preferably about 0.3 mg to about 3 mg, more preferably about 1.5 mg Vitamin E.
  • Soy isoflavones preferably about 10 mg to about 200 mg, more preferably about 90 mg
  • Inulin/Fructo-oligosaccharide (FOS) blend preferably about 4 g to about 50 g, more preferably about 6 g
  • Caseinglycomacropeptide (CGMP) preferably about 1 g to about 100 g, more preferably about 5 g
  • Casein phosphopeptide preferably about 0.1 g to about 10 g, more preferably about 0.5 g.
  • an embodiment of a method according to the invention comprises the steps of blending the nutrients, minerals or vitamins in the required amounts and/or extruding the blended mixture. More preferably it includes spray drying the mixture.
  • An advantage of the present invention is that it provides a nutritional composition that can be disolved instantaneously in water to provide a beverage or soup. It does not require cooking.
  • Another advantage of the present invention is that it provides a single composition that can be adapted and administered simply in a food for the prevention or treatment of a bone condition.
  • the compostion can be provided in clinical or performance nutrition settings and is particularly suitable for an elderly patient.
  • Yet another advantage of the present invention is that it provides a composition beneficial for diabetics. This is due to the specific composition of macronutrients, protein, carbohydrate and fat which provides a low glycemic index.
  • a nutritional composition comprises a source of protein.
  • the protein source preferably provides about 5% to about 55% of the energy of the nutritional formula; for example about 20% to about 50%, preferably 26%, of the energy.
  • Dietary protein is preferred as a source of protein.
  • the dietary protein may be any suitable dietary protein; for example animal protein (such as milk protein, meat protein or egg protein); vegetable protein (such as soy protein, wheat protein, rice protein, and pea protein); a mixture of free amino acids; or a combination thereof. Milk proteins such as casein, whey proteins and soy proteins are particularly preferred.
  • the composition also comprises a source of carbohydrates and a source of fat.
  • a fat source preferably provides about 5% to about 55% of the energy of the nutritional formula; for example about 20% to about 50%, preferably 23%, of the energy.
  • Lipid making up the fat source may be any suitable fat or fat mixture.
  • Vegetable fat is particularly suitable; for example soy oil, palm oil, coconut oil, safflower oil, sunflower oil, com oil, canola oil, lecithins, and the like. Most preferably it is a mixture of canola and soy oils.
  • Animal fat such as milk fat may also be added if desired.
  • the composition comprises saturated fat which preferably comprises about 1% to about 5%, more preferably 2.5% of the total energy of the product.
  • it comprises monounsaturated fat which preferably comprises about 5 % to about 15%, more preferably 9.9% of the total energy of the product.
  • the composition comprises polyunsaturated fat which preferably comprises about 5% to about 15%, more preferably 10.1% ofthe total energy of the product.
  • the composition comprises linoleic acid which preferably comprises about 5% to about 15%, more preferably 8.5%> of the total energy of the product.
  • the composition comprises linolenic acid which preferably comprises about 0.5% to about 5%, more preferably 1.6% ofthe total energy ofthe product.
  • the ratio of linoleic acid to linolenic acid is about 3 to about 8, more preferably about 5.3.
  • a source of carbohydrate preferably provides about 40% to about 80%, more preferably about 51% of the energy of the nutritional composition.
  • Any suitable carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin, or a mixture thereof.
  • This embodiment of the composition additionally comprises about 800mg milk calcium, about 210mg magnesium, about 15mg zinc, about lOmg of vitamin D and about 60mg of vitamin K per 300g ofthe composition.
  • Dietary fibre may also be added. It preferably comprises up to about 5% ofthe energy of the nutritional composition.
  • the dietary fibre may be from any suitable origin, preferably fructooligosaccharide, acacia gum, or a mixture thereof.
  • Isoflavone may be included. This provides the advantage of increasing bone mineral density and/or bone mineral content.
  • Calcium may be included. Preferably this calcium is derived from milk or milk protein fractions.
  • Additional suitable vitamins and minerals are included in the composition as described above.
  • Monosodium glutamate may be added as a flavour enhancer.
  • the nutritional composition is preferably used orally and could alternatively be enterally administrable; for example in the form of a powder, a liquid concentrate, or a ready-to-drink beverage. If it is desired to produce a powdered nutritional formula, the homogenized mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • a usual food product may be enriched with an embodiment of composition.
  • the amount of the composition added is preferably at least about 0.01% by weight.
  • compositions Two nutritional compositions were made by blending the required constituents. Their compositions are indicated below in Table 1. The compositions are intended to be consumed in the form of two oral supplements per day based on an enriched beverage and/or milk product desert. The total daily dose ofthe composition is intended to be approximately 300g or 300ml ofthe composition. Table 1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pediatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition nutritionnelle destinée à la prévention ou au traitement d'une pathologie osseuse. Cette composition comprend, dans une définition générale, au moins du calcium, du magnésium, du zinc, de la vitamine D et de la vitamine K. Dans un mode de réalisation de l'invention, elle comprend par exemple pour 300g: environ 800 mg de calcium, environ 210 mg de magnésium, environ 15 mg de zinc, environ 10 ug de vitamine D, environ 60 ug de vitamine K, environ 1,5 mg de cuivre, environ 5 mg de vitamine E, environ 30 mg de vitamine C, environ 90 mg d'isoflavone de soja et environ 6 g d'un mélange inuline/fructo-oligosaccharides (FOS) (30/70). La présente invention concerne un procédé de fabrication de cette composition, l'utilisation de cette composition dans la préparation d'un aliment ou d'un médicament fonctionnel, et une technique de prévention ou de traitement de pathologie osseuse qui consiste à administrer une quantité efficace de cette composition.
PCT/EP2002/000296 2001-01-08 2002-01-08 Composition nutritionnelle destinee a une pathologie osseuse WO2002052954A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02702265A EP1351584A2 (fr) 2001-01-08 2002-01-08 Composition nutritionnelle destinee a une pathologie osseuse
AU2002235836A AU2002235836A1 (en) 2001-01-08 2002-01-08 Nutritional composition for a bone condition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0100273.2A GB0100273D0 (en) 2001-01-08 2001-01-08 Nutritional composition for a bone condition
GB0100273.2 2001-01-08

Publications (2)

Publication Number Publication Date
WO2002052954A2 true WO2002052954A2 (fr) 2002-07-11
WO2002052954A3 WO2002052954A3 (fr) 2002-10-31

Family

ID=9906309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000296 WO2002052954A2 (fr) 2001-01-08 2002-01-08 Composition nutritionnelle destinee a une pathologie osseuse

Country Status (4)

Country Link
EP (1) EP1351584A2 (fr)
AU (1) AU2002235836A1 (fr)
GB (1) GB0100273D0 (fr)
WO (1) WO2002052954A2 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339294A1 (fr) * 2000-11-14 2003-09-03 Société des Produits Nestlé S.A. Composition nutritionnelle destinee a une maladie immunitaire
FR2858181A1 (fr) * 2003-07-30 2005-02-04 Christian Fenioux Preparation alimentaire hyperproteinee comportant au moins un polyphenol
WO2007009529A2 (fr) * 2005-07-19 2007-01-25 Humana Gmbh Composante peptide de calcium
WO2008012089A2 (fr) * 2006-07-28 2008-01-31 Humana Milchunion Eg Composition à base de polyphénol et de peptide
DE102006052560A1 (de) * 2006-11-06 2008-05-08 Humana Milchunion Eg Anti-diabetogene Calcium-Peptid-Zusammensetzung
WO2008064297A1 (fr) * 2006-11-21 2008-05-29 The Coca-Cola Company Boisson nutritive pour une santé osseuse optimale
US7435431B2 (en) 2004-07-28 2008-10-14 Abbott Laboratories Method for controlling body weight in estrogen-insufficient women
US20090011078A1 (en) * 2004-07-28 2009-01-08 Abbott Laboratories Nutritional compositions and methods for treating or preventing osteoporosis
NL1034964C2 (nl) * 2008-01-28 2009-07-30 Friesland Brands Bv Werkwijze en composities voor de behandeling van botaandoeningen.
US7601370B2 (en) 2004-07-28 2009-10-13 Abbott Laboratories Method for controlling body weight in estrogen-insufficient women
WO2009040089A3 (fr) * 2007-09-11 2009-10-29 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009153065A1 (fr) * 2008-06-19 2009-12-23 N.V. Nutricia Composition nutritionnelle pour patients de chirurgie bariatrique
WO2010085535A1 (fr) * 2009-01-23 2010-07-29 Wyeth Llc Compléments alimentaires pour individus de 50 ans et plus permettant d'améliorer la vitalité, l'immunité et la santé oculaire et osseuse
EP2292102A1 (fr) * 2009-09-02 2011-03-09 Lipofoods, S.L. Microcapsules contenant des sels pour produits alimentaires
FR2963725A1 (fr) * 2010-08-16 2012-02-17 Holymark Composition alimentaire pour prevenir et limiter la perte de masse musculaire, la perte de densite minerale osseuse et le declin cognitif, en particulier chez les personnes agees de 50 ans et plus
US8372442B2 (en) 2008-06-19 2013-02-12 N.V. Nutricia Liquid nutritional composition for bariatric surgery patients
EP2687106A1 (fr) * 2007-12-05 2014-01-22 N.V. Nutricia Composition nutritionnelle entérale liquide ayant une teneur énergétique élevée
US8663679B2 (en) 2004-04-29 2014-03-04 Abbott Laboratories Compositions for improving breast health in women
CN104472708A (zh) * 2014-11-26 2015-04-01 东北农业大学 一种预防和治疗妇女更年期综合症疾病的奶粉及其制备方法
CN115399473A (zh) * 2021-05-27 2022-11-29 深圳市回春堂健康管理服务有限公司 一种增加骨密度的牦牛骨髓高钙蛋白粉组合物及制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107853702A (zh) * 2017-11-03 2018-03-30 广州彤博士健康科技有限公司 复合微晶粉配方及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721742A1 (fr) * 1995-01-13 1996-07-17 Clintec Nutrition Company, An Illinois Partnership Nutrition pour patients âgés
US5827526A (en) * 1995-07-11 1998-10-27 Abbott Laboratories Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans
WO1999026491A1 (fr) * 1997-11-24 1999-06-03 Bristol-Myers Squibb Company Systemes d'apport de confiserie enrichie et procedes de preparation de ceux-ci
WO1999053777A1 (fr) * 1998-04-22 1999-10-28 Novartis Nutrition Ag Complement nutritionnel pour femmes enceintes et allaitantes
US5985339A (en) * 1996-11-22 1999-11-16 Kamarei; A. Reza Refrigeration-shelf-stable ready-to-drink complete nutritional compositions and products

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721742A1 (fr) * 1995-01-13 1996-07-17 Clintec Nutrition Company, An Illinois Partnership Nutrition pour patients âgés
US5827526A (en) * 1995-07-11 1998-10-27 Abbott Laboratories Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans
US5985339A (en) * 1996-11-22 1999-11-16 Kamarei; A. Reza Refrigeration-shelf-stable ready-to-drink complete nutritional compositions and products
WO1999026491A1 (fr) * 1997-11-24 1999-06-03 Bristol-Myers Squibb Company Systemes d'apport de confiserie enrichie et procedes de preparation de ceux-ci
WO1999053777A1 (fr) * 1998-04-22 1999-10-28 Novartis Nutrition Ag Complement nutritionnel pour femmes enceintes et allaitantes

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339294B1 (fr) * 2000-11-14 2006-08-23 Société des Produits Nestlé S.A. Composition nutritionnelle destinee a une maladie immunitaire
EP1339294A1 (fr) * 2000-11-14 2003-09-03 Société des Produits Nestlé S.A. Composition nutritionnelle destinee a une maladie immunitaire
FR2858181A1 (fr) * 2003-07-30 2005-02-04 Christian Fenioux Preparation alimentaire hyperproteinee comportant au moins un polyphenol
US8663679B2 (en) 2004-04-29 2014-03-04 Abbott Laboratories Compositions for improving breast health in women
US7435431B2 (en) 2004-07-28 2008-10-14 Abbott Laboratories Method for controlling body weight in estrogen-insufficient women
US7601370B2 (en) 2004-07-28 2009-10-13 Abbott Laboratories Method for controlling body weight in estrogen-insufficient women
US20090011078A1 (en) * 2004-07-28 2009-01-08 Abbott Laboratories Nutritional compositions and methods for treating or preventing osteoporosis
WO2007009529A2 (fr) * 2005-07-19 2007-01-25 Humana Gmbh Composante peptide de calcium
DE102005033630A1 (de) * 2005-07-19 2007-01-25 Humana Gmbh Calcium-Peptid-Komponente
WO2007009529A3 (fr) * 2005-07-19 2007-06-28 Humana Gmbh Composante peptide de calcium
EA016259B1 (ru) * 2005-07-19 2012-03-30 Хумана Мильхунион Эг Применение кальций-пептидного компонента для снижения веса тела
WO2008012089A2 (fr) * 2006-07-28 2008-01-31 Humana Milchunion Eg Composition à base de polyphénol et de peptide
EA015701B1 (ru) * 2006-07-28 2011-10-31 Хумана Мильхунион Эг Полифенольно-пептидная композиция, содержащая эпикатехин и гликомакропептид из молочной сыворотки, способ ее получения и применение композиции для укрепления здоровья кишечника
WO2008012089A3 (fr) * 2006-07-28 2008-03-27 Humana Milchunion Eg Composition à base de polyphénol et de peptide
EA016545B1 (ru) * 2006-11-06 2012-05-30 Хумана Мильхунион Эг Применение кальций-пептидной композиции для профилактики и/или лечения сахарного диабета ii типа
WO2008055801A3 (fr) * 2006-11-06 2008-12-04 Humana Milchunion Eg Composition calcium-peptide anti-diabétogène
WO2008055801A2 (fr) * 2006-11-06 2008-05-15 Humana Milchunion Eg Composition calcium-peptide anti-diabétogène
DE102006052560A1 (de) * 2006-11-06 2008-05-08 Humana Milchunion Eg Anti-diabetogene Calcium-Peptid-Zusammensetzung
DE102006052560B4 (de) * 2006-11-06 2010-01-21 Humana Milchunion Eg Anti-diabetogene Calcium-Peptid-Zusammensetzung
WO2008064297A1 (fr) * 2006-11-21 2008-05-29 The Coca-Cola Company Boisson nutritive pour une santé osseuse optimale
WO2009040089A3 (fr) * 2007-09-11 2009-10-29 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
EP2687106B1 (fr) 2007-12-05 2018-05-02 N.V. Nutricia Composition nutritionnelle entérale liquide ayant une teneur énergétique élevée
EP2687106A1 (fr) * 2007-12-05 2014-01-22 N.V. Nutricia Composition nutritionnelle entérale liquide ayant une teneur énergétique élevée
WO2009095240A1 (fr) * 2008-01-28 2009-08-06 Friesland Brands B.V. Procédés et compositions pour le traitement d'affections osseuses
EA020252B1 (ru) * 2008-01-28 2014-09-30 Фрисланд Брандз Б.В. Способы и композиции для лечения заболеваний костей
NL1034964C2 (nl) * 2008-01-28 2009-07-30 Friesland Brands Bv Werkwijze en composities voor de behandeling van botaandoeningen.
WO2009153065A1 (fr) * 2008-06-19 2009-12-23 N.V. Nutricia Composition nutritionnelle pour patients de chirurgie bariatrique
US8372442B2 (en) 2008-06-19 2013-02-12 N.V. Nutricia Liquid nutritional composition for bariatric surgery patients
US9398776B2 (en) 2009-01-23 2016-07-26 Wyeth Llc Nutritional supplements for 50+ individuals for improving vitality, immunity, eye and bone health
WO2010085535A1 (fr) * 2009-01-23 2010-07-29 Wyeth Llc Compléments alimentaires pour individus de 50 ans et plus permettant d'améliorer la vitalité, l'immunité et la santé oculaire et osseuse
RU2663017C2 (ru) * 2009-01-23 2018-08-01 ВАЙЕТ ЭлЭлСи Пищевые добавки для лиц в возрасте 50 лет и старше для повышения жизнеспособности, иммунитета, здоровья глаз и костей
WO2011026612A1 (fr) * 2009-09-02 2011-03-10 Lipofoods, S.L. Microcapsules contenant des sels pour des produits alimentaires
EP2292102A1 (fr) * 2009-09-02 2011-03-09 Lipofoods, S.L. Microcapsules contenant des sels pour produits alimentaires
FR2963725A1 (fr) * 2010-08-16 2012-02-17 Holymark Composition alimentaire pour prevenir et limiter la perte de masse musculaire, la perte de densite minerale osseuse et le declin cognitif, en particulier chez les personnes agees de 50 ans et plus
CN104472708A (zh) * 2014-11-26 2015-04-01 东北农业大学 一种预防和治疗妇女更年期综合症疾病的奶粉及其制备方法
CN115399473A (zh) * 2021-05-27 2022-11-29 深圳市回春堂健康管理服务有限公司 一种增加骨密度的牦牛骨髓高钙蛋白粉组合物及制备方法

Also Published As

Publication number Publication date
GB0100273D0 (en) 2001-02-14
WO2002052954A3 (fr) 2002-10-31
AU2002235836A1 (en) 2002-07-16
EP1351584A2 (fr) 2003-10-15

Similar Documents

Publication Publication Date Title
US6929793B2 (en) Nutritional composition for treating an immune condition
EP1351584A2 (fr) Composition nutritionnelle destinee a une pathologie osseuse
AU2002221860A1 (en) Nutritional composition for an immune condition
CN102687750B (zh) 一种减肥代餐蛋白型固体饮料
CN103054046B (zh) 高能量液体肠营养组合物
RU2385647C2 (ru) Питание для пациентов, страдающих ожирением
CN106473153A (zh) 全营养配方食品及其制备方法
EP1401293A1 (fr) Complement liquide buvable hautement calorique
NO333819B1 (no) Spedbarn- eller barne-ernæringssammensetning omfattende sialsyre og fremgangsmåte for fremstilling
WO2009072869A1 (fr) Composition nutritionnelle entérale liquide à haute énergie
FI107014B (fi) Terveysravintovalmiste
KR20100016068A (ko) 고농도의 나트륨을 함유한 액상 영양 조성물 및 그의 제조 방법
US20030091613A1 (en) Gelled nutritional composition and process
KR20060024766A (ko) 혈중 저분자량질소함유화합물의 농도를 저감시키는질병개선용식품
US20240225072A1 (en) Infant formula for feeding infants receiving infant formula and human breast milk
AU2022287240A1 (en) Infant formula for feeding infants receiving infant formula and human breast milk
KR20160058475A (ko) 비타민 b군과 타우린을 함유한 빙과류 조성물 및 그의 제조방법
JP2024043948A (ja) 腸内のアンモニア濃度低減用組成物
Lloyd US whey products and child nutrition
WO2014157717A1 (fr) Aliment semi-solide hautement nutritif
WO2019223819A1 (fr) Composition nutritionnelle
AU2002312973A1 (en) Calorically dense liquid oral supplement
JP2007077070A (ja) 更年期の肥満防止剤または肥満改善剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002702265

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002702265

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002702265

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP